CADTH | Evidence Driven
CADTH | Evidence Driven

ruxolitinib

Details

Generic Name:
ruxolitinib
Project Status:
Pending
Therapeutic Area:
atopic dermatitis
Manufacturer:
Incyte Biosciences Canada Corporation
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0807-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of atopic dermatitis in patients 12 years of age and older whose disease is not adequately controlled with conventional topical prescription therapies (topical calcineurin inhibitors, topical corticosteroids) or when those therapies are not advisable.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
ruxolitinib cream is indicated for topical treatment of atopic dermatitis in patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : September 14, 2023